/ASLN
ASLN Stock - ASLAN Pharmaceuticals Limited
Healthcare|BiotechnologyNASDAQ
$0.60-14.27%
$0.10 (-14.27%) • Jul 18
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.64
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ASLN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.59 – $0.61
TARGET (TP)$0.69
STOP LOSS$0.55
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.40
52W High$17.04
52W Low$0.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $12.00M | N/A | N/A | N/A | $3.00M |
| Gross Profit | $11.65M | $-331,752 | $-282,224 | $-297,758 | $2.59M |
| Gross Margin | 97.1% | N/A | N/A | N/A | 86.4% |
| Operating Income | $-43,735,600 | $-47,882,487 | $-33,846,452 | $-16,483,297 | $-45,578,975 |
| Net Income | $-44,219,604 | $-51,382,417 | $-34,709,218 | $-17,906,210 | $-47,065,537 |
| Net Margin | -368.5% | N/A | N/A | N/A | -1568.9% |
| EPS | $-10.76 | $-14.72 | $-10.64 | $-9.32 | $-29.00 |
Company Overview
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ASLNBeat Rate
50%
Last 20 quarters
Avg Surprise
-33.3%
EPS vs Estimate
Beats / Misses
10/8
2 met exactly
Latest EPS
$-0.88
Q3 2024
EPS Surprise History
Q4 22
+20.0%
$-6.40vs$-8.00
Q1 23
-9.5%
$-8.32vs$-7.60
Q2 23
-61.2%
$-10.32vs$-6.40
Q3 23
+87.4%
$-0.88vs$-6.96
Q4 23
+34.1%
$-4.48vs$-6.80
Q1 24
-20.0%
$-0.78vs$-0.65
Q2 24
-923.0%
$-6.24vs$-0.61
Q3 24
+75.6%
$-0.88vs$-3.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 9, 2024 | $-3.60 | $-0.88 | +75.6% | ✓ BEAT |
Q2 2024 | Apr 12, 2024 | $-0.61 | $-6.24 | -923.0% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-0.65 | $-0.78 | -20.0% | ✗ MISS |
Q4 2023 | Oct 27, 2023 | $-6.80 | $-4.48 | +34.1% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-6.96 | $-0.88 | +87.4% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | $-6.40 | $-10.32 | -61.2% | ✗ MISS |
Q1 2023 | Mar 24, 2023 | $-7.60 | $-8.32 | -9.5% | ✗ MISS |
Q4 2022 | Oct 28, 2022 | $-8.00 | $-6.40 | +20.0% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-8.00 | $-7.60 | +5.0% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $-6.80 | $-7.60 | -11.8% | ✗ MISS |
Q1 2022 | Mar 25, 2022 | $-6.00 | $-6.40 | -6.7% | ✗ MISS |
Q4 2021 | Oct 26, 2021 | $-4.80 | $-4.80 | 0.0% | = MET |
Q3 2021 | Aug 6, 2021 | $-4.40 | $-3.20 | +27.3% | ✓ BEAT |
Q2 2021 | Apr 22, 2021 | $-2.75 | $-6.00 | -118.2% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | $-2.75 | $-0.72 | +73.9% | ✓ BEAT |
Q4 2020 | Nov 9, 2020 | $-4.00 | $-0.80 | +80.0% | ✓ BEAT |
Q3 2020 | Jul 13, 2020 | $-4.00 | $-4.00 | 0.0% | = MET |
Q2 2020 | May 11, 2020 | $-4.40 | $-3.20 | +27.3% | ✓ BEAT |
Q1 2020 | Mar 19, 2020 | $-6.00 | $-8.00 | -33.3% | ✗ MISS |
Q4 2019 | Oct 31, 2019 | $-8.80 | $-1.20 | +86.4% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ASLN
What is ASLN's current stock price?
ASLAN Pharmaceuticals Limited (ASLN) is currently trading at $0.60 per share. The stock has moved -14.27% today.
What is the analyst price target for ASLN?
No analyst price targets are currently available for this stock.
What sector is ASLAN Pharmaceuticals Limited in?
ASLAN Pharmaceuticals Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ASLN's market cap?
ASLAN Pharmaceuticals Limited has a market capitalization of $0.78 billion, making it a small-cap company.
Does ASLN pay dividends?
No, ASLAN Pharmaceuticals Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALBO
Albireo Pharma, Inc.
$44.15
Mkt Cap: $0.9B
CDMO
Avid Bioservices, Inc.
$12.49
Mkt Cap: $0.8B
CMRX
Chimerix, Inc.
$8.54
Mkt Cap: $0.8B
EXAI
Exscientia plc
$4.84
Mkt Cap: $0.6B
HARP
Harpoon Therapeutics, Inc.
$23.01
Mkt Cap: $0.9B
ICPT
Intercept Pharmaceuticals, Inc.
$19.00
Mkt Cap: $0.8B
ICVX
Icosavax, Inc.
$15.31
Mkt Cap: $0.8B
IKNA
Ikena Oncology, Inc.
$17.16
Mkt Cap: $0.7B
NAGE
Niagen Bioscience Inc
$6.51
Mkt Cap: $0.5B
PSTX
Poseida Therapeutics, Inc.
$9.50
Mkt Cap: $0.9B
Explore stocks similar to ASLN for comparison